Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space
This article was originally published in The Tan Sheet
Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.
You may also be interested in...
After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.